Amarin Corporation plc, a Dublin-based pharmaceutical company focused on the development and commercialization of treatments for cardiovascular diseases, is expanding its reach worldwide. Its flagship product, VASCEPA, a prescription-only omega-3 fatty acid medication used to reduce triglyceride levels in adult patients with severe hypertriglyceridemia, is currently available in the United States, Canada, various European countries, Lebanon, and the United Arab Emirates. Amarin Corporation plc primarily sells its products to wholesalers and specialty pharmacy providers, and has a partnership with Mochida Pharmaceutical Co., Ltd. to create and sell drug products and indications using the active ingredient in VASCEPA. Originally named Ethical Holdings plc, Amarin Corporation plc has been in operation since 1989 and underwent a name change in 1999.
Amarin Corporation's ticker is AMRN
The company's shares trade on the NASDAQ stock exchange
They are based in Dublin, Ireland
There are 501-1000 employees working at Amarin Corporation
It is amarincorp.com
Amarin Corporation is in the Healthcare sector
Amarin Corporation is in the Biotechnology industry
The following five companies are Amarin Corporation's industry peers: